Safety and Efficacy of SH T00660AA in Treatment of Endometriosis

NCT00225186 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2014-01-09

No results posted yet for this study

Summary

The purpose of this study is to demonstrate safety and efficacy of SH T00660AA for the treatment of endometriosis

Conditions

  • Endometriosis

Interventions

DRUG

Visanne (SH T00660AA , BAY86-5258)

Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Germany
  • Italy
  • Ukraine

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00225186 on ClinicalTrials.gov